Table 4. Published population-based studies investigating blood levels of natriuretic peptides as risk predictors for mortality.
| Author | Study | Year of publication | Number of subjects | Age (mean ±SD) [years] | Median follow-up [years] | Natriuretic peptide used (additional measured peptide) | Outcome | Number of events | HR** | P-value | Echo data |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Our study | KORA-S3 | 1,223 | 49.7±13.7 | 12.9 | NT-proBNP (BNP) | All-cause mortality | 99 | 1.43 | 0.001 | LVM, EF, LVD, LAEn, diastolic function | |
| CVD death | 55 | 1.67, 1.73† | <0.001,0.047† | ||||||||
| Patterson et al. | CaPS | 2015 | 1,773 men | * | 15.4 | BNP | CVD death | 355 | 1.54‡ | <0.001‡ | None |
| Linssen et al. | PREVEND | 2010 | 8,383 | 49±12.7 | 7.5 | NT-proBNP | All-cause mortality | 437 | 1.22 | <0.001 | None |
| Laukkanen et al. | KIHD | 2006 | 905 men | 55.8±6.6 | 10 | NT-proBNP (NT-proANP) | All-cause mortality | 110 | 1.26 | <0.001 | None |
| CVD death | 58 | 1.41 | <0.001 | ||||||||
| McKie et al. | Olmsted County | 2006 | 1,991 | 62±10 | 5.6 | NT-proBNP (BNP) | All-cause mortality | 106 | 1.75, 1.44§ | <0.001, 0.014§ | LVM, LVD, diastolic/valvular function, LAEn, RWMA |
| Kistorp et al. | Copenhagen | 2005 | 626 | 67.9±10.6 | 5 | NT-proBNP | All-cause mortality | 94 | 1.55 | 0.001 | None |
| Wang et al. | Framingham Offspring | 2004 | 3,346 | 59±10 (men)/ 58±10 (women) | 5.2 | BNP (NT-proANP) | All-cause mortality | 119 | 1.27ǁ | 0.009ǁ, 0.29¶ | LVM, LVD, LAEn |
HR: hazard ratio per 1 unit increase in lnNT-proBNP (our study), per third of BNP distribution (CaPS), per 1 unit increase in log2NT-proBNP (PREVEND), per 1SD-increment in log variable (KIHD, Olmsted, Copenhagen, Framingham). CVD: cardiovascular disease. LVM: left ventricular mass. EF: left ventricular ejection fraction. LVD: left ventricular systolic dysfunction. LAEn: left atrial enlargement. RWMA: regional wall motion abnormalities.
* predominantly aged 55–69 at baseline.
** adjusted for age and sex (if not indicated otherwise).
† Adjustment for clinical risk factors and echo, in detail: age, sex, serum creatinine, ratio of total to high density lipoprotein, hypertension, diabetes, BMI, LVMi, diastolic dysfunction, EF.
‡ adjusted for age, smoking, diabetes, systolic blood pressure, total cholesterol, total triglycerides, BMI, history of CVD, positive family history of coronary heart disease.
§ Adjustment for clinical risk factors and echo, in detail: age, sex, serum creatinine, total cholesterol, hypertension, diabetes, coronary artery disease, presence of EF <50%, diastolic dysfunction, valvular dysfunction, LVH, LAEn, RWMA.
ǁ adjusted for age, sex, serum creatinine, ratio of total to high-density lipoprotein, hypertension, diabetes, BMI, smoking status.
¶ extends the adjustment of ǁ by adding LVH, LVD, LAEn.